Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Serum uric acid may protect against hip osteoporosis in postmenopausal RA patients

Key clinical point: In postmenopausal women with rheumatoid arthritis (RA), serum uric acid (UA) may exert a protective effect against hip osteoporosis.

Major finding: Patients with RA showed a significantly lower risk for osteoporosis of the hip within the highest quartile (odds ratio [OR], 0.37; P = .021) and the second highest quartile (OR, 0.44; P = .038) of serum UA levels compared with the lowest quartile. Serum UA levels positively correlated with femoral neck bone mineral density (BMD; β = 0.0104; P = .01) and total hip BMD (β = 0.0102; P = .017), but not with lumbar BMD.

Study details: The data come from a retrospective cross-sectional study involving 447 postmenopausal women with RA and 200 age-matched postmenopausal healthy controls.

Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Citation:

Lee HN et al. Medicine (Baltimore). 2020 Jun 12. doi: 10.1097/MD.0000000000020633.